Anti-Inflammatory Effects of ∆9 Tetrahydrocannabinol in Adipose Tissue of an Obese Rat Model

Journal of Chemical Health Risks

مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 27 آبان 1402   

نوع مقاله: Original Article

شناسه دیجیتال (DOI): 10.22034/jchr.2023.1975620.1659

نویسندگان

Seyyede Fahimeh Mirseyyed¹؛ Saeed Zavareh^{* 2}؛ Meysam Nasiri²؛ Hamid Hashemi Moghadam³

¹Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran

²School of Biology, Damghan University, Damghan, Iran

³Department of Chemistry, Damghan Branch, Islamic Azad University, Damghan, Iran

چکیده

This study sought to investigate how ∆9 Tetrahydrocannabinol (THC) affects inflammation within the adipose tissue of an obese rat model. Female Sprague-Dawley rats, aged 4 weeks (total: 15 rats), were divided into four groups: Control, which received a standard diet; Obese, which were fed a high-fat diet (HFD); and THC, which received both THC treatment and an HFD. After a 16-week period, we measured their body weight and C-reactive protein (CRP) levels. Adipose tissue samples were collected to analyze the expression levels of Mcp, Tnf-α, and Il-1β mRNA. The obese rats showed a significant increase in body weight compared to the other groups, while the THC-treated group exhibited significantly lower weights than the obese rats. CRP levels were notably higher in the obese group than in the other groups, but CRP levels in the THC group were significantly lower than in the obese group. Expression levels of Mcp, Tnf-α, and Il-1β mRNA were markedly higher in the obese group compared to the control. In contrast, the THC group displayed significantly lower mRNA expression levels than the obese group. Treatment with a low dose of THC resulted in a reduction of inflammation markers in the adipose tissue of obese rats.

کلیدواژه‌ها

Inflammation؛ Obesity, THC؛ Rat

مراجع

1. 1. Wu S., Divall S., Nwaopara A., Radovick S., Wondisford F., Ko C., Wolfe A., 2014. Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes. 63(4), 1270-1282.
2. 2. Ressler I.B., Grayson B.E., Ulrich-Lai Y.M., Seeley R.J., 2015. Diet-induced obesity exacerbates metabolic and behavioral effects of polycystic ovary syndrome in a rodent model. American Journal of Physiology-Endocrinology and Metabolism. 308 (12), E1076-E1084.
3. 3. Wang M.X., Yin Q., Xu X., 2020. A rat model of polycystic ovary syndrome with insulin resistance induced by letrozole combined with high fat diet. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 26, e922136-922131.
4. Festa A., D’Agostino Jr R., Howard G., Mykkanen L., Tracy R. P., Haffner S. M., 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 102 (1), 42-47.
5. Yesildag K., Gur C., Ileriturk M., Kandemir F.M., 2022. Evaluation of oxidative stress, inflammation, apoptosis, oxidative DNA damage and metalloproteinases in the lungs of rats treated with cadmium and carvacrol. Molecular Biology Reports. 49(2), 1201-1211.
6. 6. Spritzer P.M., Lecke S.B., Satler F., Morsch D.M., 2015. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary

 

 

syndrome. Reproduction. 149(5), R219-R227.

7. 7. Katchan V., David P., Shoenfeld Y., 2016.Cannabinoids and autoimmune diseases: systematic review. Autoimmunity Reviews. 15(6), 513-528.
8. Massi P., Vaccani A., Parolaro D., 2006. Cannabinoids, immune system and cytokine network. Current Pharmaceutical Design. 12(24), 3135-3146.
9. 9. Larsen C., Shahinas J., 2020. Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. Journal of Clinical Medicine Research. 12(3), 129.

10 . Xu J., Dun J., Yang J., Zhang J., Lin Q., Huang M., Ji F., Huang L., You X., Lin Y., 2020. Letrozole rat model mimics human polycystic ovarian syndrome and changes in insulin signal pathways. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 26, e923073-923071.

11. 11. Zhang H., Yi M., Zhang Y., Jin H., Zhang W., Yang J., Yan L., Li R., Zhao Y., Qiao J., 2016. High-fat diets exaggerate endocrine and metabolic phenotypes in a rat model of DHEA-induced PCOS. 151 (4), 431-441.
12. 12. Bagheripour N., Zavareh S., Ghorbanian M.T., Paylakhi S.H., Mohebbi S.R., 2017. Changes in the expression of OCT4 in mouse ovary during estrous cycle.  Veterinary Research Forum. 8 (1), 43-48.
13. 13. Kelly C.C.J., Lyall H., Petrie J.R., Gould G.W., Connell J.M.C., Sattar N., 2001. Low Grade Chronic Inflammation in Women with Polycystic Ovarian Syndrome. The Journal of Clinical Endocrinology & Metabolism. 86(6), 2453-2455.
14. 14. González F., Rote N.S., Minium J., Kirwan J.P., 2006. Increased activation of nuclear factor κB triggers inflammation and insulin resistance in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 91(4), 1508-1512.
15. Avraham Y., Ben-Shushan D., Breuer A., Zolotarev O., Okon A., Fink N., Katz V., Berry E. M., 2004. Very low doses of Δ8-THC increase food consumption and alter neurotransmitter levels following weight loss. Pharmacology Biochemistry and Behavior. 77(4), 675-684.
16. 16. Le Foll B., Trigo J. M., Sharkey K. A., Le Strat Y., 2013. Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss? Medical Hypotheses. 80(5), 564-567.
17. 17. Mastinu A., Premoli M., Ferrari-Toninelli G., Tambaro S., Maccarinelli G., Memo M., Bonini S. A., 2018. Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation. Hormone Molecular Biology and Clinical Investigation. 36(2), 1-15.
18. 18. Assa-Glazer T., Gorelick J., Sela N., Nyska A., Bernstein N., Madar Z., 2020. Cannabis extracts affected metabolic syndrome parameters in mice fed high-fat/cholesterol diet. Cannabis and Cannabinoid Research. 5(3), 202-214.
19. 19. Rajavashisth T.B., Shaheen M., Norris K.C., Pan D., Sinha S. K., Ortega J., Friedman T. C., 2012. Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. BMJ Open. 2(1), e000494.
20. 20. Carrieri M.P., Serfaty L., Vilotitch A., Winnock M., Poizot-Martin I., Loko M.A., Lions C., Lascoux-Combe C., Roux P., Salmon-Ceron D., Spire B., Dabis F., Group f. t. A. C. H. S., Salmon D., Dabis F., Winnock M., Loko
21. A., Sogni P., Benhamou Y., Trimoulet P., Izopet J., Paradis V., Spire B., Carrieri P., 2015. Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). Clinical Infectious Diseases, 61(1), 40-48.
22. 21. Cao R., Wang J., Zhang W., Huang H., Qiao Y., Dai Y., Gong M., Lai H. C., 2017. Is Marijuana Beneficial for Prevention and Treatment of Diabetes? Am J Biomed Sci. 9(4), 200-210.
23. 22. Li Z., Peng A., Feng Y., Zhang X., Liu F., Chen C., Ye X., Qu J., Jin C., Wang M., 2019. Detection of T lymphocyte subsets and related functional molecules in follicular fluid of patients with polycystic ovary syndrome. Scientific Reports. 9(1), 1-10.
24. 23. Ahmed W., Katz S., 2016. Therapeutic use of cannabis in inflammatory bowel disease. Gastroenterology & hepatology, 12(11), 668.